These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy. Pisonero-Vaquero S; González-Gallego J; Sánchez-Campos S; García-Mediavilla MV Curr Med Chem; 2015; 22(25):2991-3012. PubMed ID: 26242257 [TBL] [Abstract][Full Text] [Related]
4. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Van De Wier B; Koek GH; Bast A; Haenen GR Crit Rev Food Sci Nutr; 2017 Mar; 57(4):834-855. PubMed ID: 25897647 [TBL] [Abstract][Full Text] [Related]
5. Prevention and treatment effect of total flavonoids in Stellera chamaejasme L. on nonalcoholic fatty liver in rats. Wang Y; Li JY; Han M; Wang WL; Li YZ Lipids Health Dis; 2015 Aug; 14():85. PubMed ID: 26242978 [TBL] [Abstract][Full Text] [Related]
7. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Faghihzadeh F; Adibi P; Hekmatdoost A Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526 [TBL] [Abstract][Full Text] [Related]
8. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound. Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896 [TBL] [Abstract][Full Text] [Related]
9. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998 [TBL] [Abstract][Full Text] [Related]
10. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Abenavoli L; Greco M; Milic N; Accattato F; Foti D; Gulletta E; Luzza F Nutrients; 2017 Aug; 9(8):. PubMed ID: 28805669 [TBL] [Abstract][Full Text] [Related]
11. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Chachay VS; Macdonald GA; Martin JH; Whitehead JP; O'Moore-Sullivan TM; Lee P; Franklin M; Klein K; Taylor PJ; Ferguson M; Coombes JS; Thomas GP; Cowin GJ; Kirkpatrick CM; Prins JB; Hickman IJ Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2092-103.e1-6. PubMed ID: 24582567 [TBL] [Abstract][Full Text] [Related]
12. Low physical activity and energy dense Malaysian foods are associated with non-alcoholic fatty liver disease in centrally obese but not in non-centrally obese patients with diabetes mellitus. Chan WK; Tan AT; Vethakkan SR; Tah PC; Vijayananthan A; Goh KL Asia Pac J Clin Nutr; 2015; 24(2):289-98. PubMed ID: 26078246 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit? Almobarak AO; Barakat S; Suliman EA; Elmadhoun WM; Mohamed NA; Abobaker IO; Noor SK; Bushara SO; Ahmed MH Arab J Gastroenterol; 2015 Jun; 16(2):54-8. PubMed ID: 26174761 [TBL] [Abstract][Full Text] [Related]
14. Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice. Gan L; Meng ZJ; Xiong RB; Guo JQ; Lu XC; Zheng ZW; Deng YP; Luo BD; Zou F; Li H Acta Pharmacol Sin; 2015 May; 36(5):597-605. PubMed ID: 25891086 [TBL] [Abstract][Full Text] [Related]
15. Herbal medicines and nonalcoholic fatty liver disease. Yao H; Qiao YJ; Zhao YL; Tao XF; Xu LN; Yin LH; Qi Y; Peng JY World J Gastroenterol; 2016 Aug; 22(30):6890-905. PubMed ID: 27570425 [TBL] [Abstract][Full Text] [Related]
16. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Sugimoto K; Inui H; Fukusato T World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263 [TBL] [Abstract][Full Text] [Related]
17. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642 [TBL] [Abstract][Full Text] [Related]
18. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats. Jegatheesan P; Beutheu S; Freese K; Waligora-Dupriet AJ; Nubret E; Butel MJ; Bergheim I; De Bandt JP Br J Nutr; 2016 Jul; 116(2):191-203. PubMed ID: 27197843 [TBL] [Abstract][Full Text] [Related]
19. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305 [TBL] [Abstract][Full Text] [Related]